Abstract: Provided herein, in some embodiments, are methods and compositions for the treatment of Charcot-Marie-Tooth disease.

Abstract: Provided herein, in some embodiments, are methods and compositions for the treatment of Charcot-Marie-Tooth disease, comprising an inhibitor of a GCN2 pathway component.

Abstract: RNA interference-based methods and products for inhibiting the expression of mutant Glycyl-tRNA Synthetase (GARS) genes are provided. Delivery vehicles such as recombinant adeno-associated viruses deliver DMAs encoding GARS microRNAs, as well as a replacement GARS gene that is resistant to knock down by the microRNAs. The methods have application in the treatment of N diseases or disorders associated with mutant GARS including, but not limited to, Charcot-Marie-Tooth Disease Type 2D (CMT2D).

Abstract: A conveyor belt includes a self-supporting linkage assembly and a plurality of transverse elements configured to travel along a longitudinal direction. The transverse elements are interconnected by the linkage assembly. The conveyor belt also includes a biasing member. The linkage assembly includes a first link and a second link. The first and second links are configured to move relative to each other between an engaged position and a disengaged position. The biasing member is configured to bias the first and second links toward the engaged position. The first and second links, when in the engaged position, are constrained against rotation relative to each other. The first and second links, when in the disengaged position, are configured to rotate relative to each other.